Noble Life Sciences in partnership with NorthEast BioLab is hosting a webinar.
The need for expedited drug development and efficient capital allocation has placed a justified emphasis on early in vivo testing for pharmacology and disease modulation. In this webinar, we would share actionable insights from our 100+ years of collective experience managing drug discovery, pharmacokinetics (PK), and biomarker testing studies.
- Drug discovery screening process from target selectivity to potency in preclinical disease models
- In vivo proof-of-concept PK and Biomarker testing towards clinical efficacy based on drug exposure and biological response
- In vitro ADME (protein binding, metabolic stability, drug-drug interaction potential), pharmacodynamic (PD) biomarkers, and exposure-effect relationships
- PK/PD studies to assess drug safety margins, support dose selection for clinical trials, select endpoints, and benchmark pharmacological data
Dr. Stephen Horrigan
Mr. Ryan Sheeler,